2018

Impact of breast cancer molecular subtypes on the occurrence, kinetics and prognosis of central nervous system metastases in a large multicenter cohort

Congress : ESMO

Authors : Amélie Darlix1, M.D., Guillaume Louvel, M.D., Ph.D. 2, Julien Fraisse3, William Jacot1, M.D., Ph.D.1, Etienne Brain, M.D., Ph.D.4, Marc Debled, M.D.5, Marie Ange Mouret-Reynier, M.D., Ph.D.6, Anthony Goncalves, M.D., Ph.D.7, Florence Dalenc, M.D, Ph.D.8, Paule Augereau, M.D.9, Jean Marc Ferrero, M.D., Ph.D.10, Christelle Levy, M.D.11, Jean-David Fumet, M.D.12, Christelle Jouannaud, M.D.13, Corinne Veyret, M.D.14, Véronique Dieras, M.D.15, Mathieu Robain, Ph.D.16, Coralie Courtinard, MSC16, David Pasquier, M.D, Ph.D.17, Thomas Bachelot, M.D., Ph.D.18.

Experts group or program : ESMÉ - données de vie réelle en cancérologie

Metastatic breast cancer (MBC) behavior differs depending on the molecular subtype based on hormone receptors (HR) and HER2 statuses. We aimed at evaluating the kinetics of central nervous system metastases (CNSM) occurrence, and the prognosis after CNSM, according to the molecular subtype.